本文選題：腫瘤干細胞 + 卵巢癌　； 參考：《首都醫(yī)科大學》2014年碩士論文

【摘要】：目的：探討MiR-34a在卵巢癌腫瘤干細胞中的表達及其對人卵巢癌干細胞的生物學特性的影響。方法：本研究選擇人卵巢上皮性腫瘤細胞株A2780作為樣本，以CD133作為Marker，，采用流式細胞儀分選出CD133+、CD133-細胞，采用克隆實驗方法驗證CD133+細胞具有卵巢癌干細胞的生物學特性，采用RT-PCR方法比較驗證miR-34a在CD133+細胞的表達。將miR-34a重組質粒轉染給CD133+細胞，觀察卵巢癌腫瘤干細胞生物學性狀的改變，包括采用MTT法檢測增殖能力和化療敏感性，皮下接種裸鼠成瘤檢測成瘤能力。結果：培養(yǎng)14天后，CD133+細胞的克隆形成能力顯著高于CD133-細胞(P0．01)，且CD133+細胞能形成更大的克隆；miR-34a在CD133+細胞中低表達；培養(yǎng)1、2、3、4、5、6d后，轉染miR-34a CD133+細胞與未轉染miR-34a CD133+細胞（對照組）相比，細胞增殖能力降低(P0．05)；紫杉醇低至高濃度作用下，轉染miR-34a CD133+細胞的耐藥性低于對照組，細胞藥物敏感性差異具有顯著統(tǒng)計學意義(P0．01)；轉染miR-34a CD133+細胞較未轉染miR-34a CD133+細胞致瘤能力顯著降低，相同數量的未轉染miR-34a CD133+細胞在同一觀察時間點可以形成更大的腫瘤，且形成腫瘤的潛伏期較短。結論：1、CD133可以作為卵巢癌腫瘤干細胞表面的標志性分子之一；2、miR-34a在卵巢癌腫瘤干細胞中低表達；3、miR-34a在卵巢癌中發(fā)揮潛在的抑癌基因作用，增加miR-34a的表達，可明顯抑制細胞的增殖、成瘤能力及耐藥性，大大降低了腫瘤細胞的惡性度；4、miR-34a可成為一個治療卵巢癌的潛在基因靶點，可能為卵巢癌的治療提供一條新的生物途徑。
[Abstract]:Aim: to investigate the expression of MiR-34a in ovarian cancer stem cells and its effect on the biological characteristics of human ovarian cancer stem cells. Methods: in this study, human ovarian epithelial tumor cell line A2780 was selected as sample, CD133 as marker, CD133 CD133- cells were separated by flow cytometry, and the biological characteristics of ovarian cancer stem cells were verified by clone assay. The expression of miR-34a in CD133 cells was compared by RT-PCR method. The miR-34a recombinant plasmid was transfected into CD133 cells to observe the changes of biological characteristics of ovarian cancer stem cells. The proliferation and chemosensitivity of ovarian cancer stem cells were detected by MTT method and tumorigenic ability was detected by subcutaneous inoculation of nude mice. Results: after 14 days of culture, the clone forming ability of CD133 cells was significantly higher than that of CD133- cells, and CD133 cells could form a larger clone of miR-34a in CD133 cells, and after 6 days of culture, the transfected miR-34a CD133 cells were compared with those of untransfected miR-34a CD133 cells (control group). The drug resistance of miR-34a CD133 cells transfected with paclitaxel at low to high concentration was lower than that in control group. The chemosensitivity of miR-34a CD133 cells was significantly lower than that of untransfected miR-34a CD133 cells, and the same number of untransfected miR-34a CD133 cells could form larger tumors at the same observation time point. And the incubation period of tumor formation is short. Conclusion 1: 1 + CD133 can play a potential role as a tumor suppressor gene in ovarian cancer cells, increase the expression of miR-34a, and inhibit the proliferation of ovarian cancer cells, which is one of the signature molecules on the surface of ovarian cancer stem cells. The ability of tumorigenesis and drug resistance have greatly reduced the malignancy of tumor cells. 4miR-34a may become a potential gene target for the treatment of ovarian cancer and may provide a new biological pathway for the treatment of ovarian cancer.
【學位授予單位】：首都醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R737.31

【共引文獻】

相關期刊論文 前4條

1 宋菁華;王克芳;李斌;張軍;;人宮頸癌側群細胞的分選及其生物學特性的研究[J];首都醫(yī)科大學學報;2012年01期

2 李雪;汪學非;唐兆慶;沈振斌;孫益紅;施前;湯其群;秦新裕;;胃癌側群細胞檢測分選及其增殖能力的初步分析[J];復旦學報(醫(yī)學版);2009年01期

3 陳偉;姜楠;張彤;李華;張琪;陳規(guī)劃;曾憲成;;肝癌細胞株Bel-7402中側群細胞的分離和致瘤能力[J];中山大學學報(醫(yī)學科學版);2012年05期

4 韓琪;李斌;王克芳;宋菁華;;腫瘤干細胞與microRNA的研究進展[J];中國腫瘤臨床;2013年05期

相關碩士學位論文 前1條

1 張偉;四君子湯藥物血清對人胃癌細胞株BGC-823、SGC-7901側群細胞生物學特性的影響[D];蚌埠醫(yī)學院;2013年

本文編號：1920591